Extended-release Naltrexone for Alcohol Dependence in Primary Care

This study has been completed.
Sponsor:
Collaborator:
Alkermes
Information provided by (Responsible Party):
Marc Gourevitch, New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00620750
First received: February 11, 2008
Last updated: August 22, 2011
Last verified: August 2011

February 11, 2008
August 22, 2011
July 2007
November 2008   (final data collection date for primary outcome measure)
Percent of Patients Initiating Vivitrol Treatment Who Receive 3 Consecutive Monthly Vivitrol Injections [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00620750 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Extended-release Naltrexone for Alcohol Dependence in Primary Care
Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study

Naltrexone is an opioid antagonist with a high affinity for the mu opioid receptor. The efficacy of extended-release naltrexone (Vivitrol) as a treatment for alcohol dependence has been demonstrated in clinical trials, raising the prospect of integrating pharmacologic treatment for alcohol dependence into general medical care settings. However, the feasibility of implementing this United States Food and Drug Administration approved treatment in the front-line settings in which it is most needed has not been demonstrated. This is an open-label pilot feasibility study of implementing treatment with Vivitrol in primary care medical clinics in a safety net hospital system affiliated with an urban academic center.

Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Alcohol Dependence
Drug: Extended release injectable naltrexone (Vivitrol)
Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
Other Name: Vivitrol
Experimental: Extended release injectable naltrexone
Intervention: Drug: Extended release injectable naltrexone (Vivitrol)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
February 2010
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Current alcohol dependence
  • Age 18 or older
  • English or Spanish-speaking
  • Without untreated severe mental illness
  • Liver enzymes (alanine aminotransferase and aspartate aminotransferase) ≤ 3x normal
  • Kept 2 of last 3 clinic primary care appointments and/or has a working telephone number at which can be contacted directly
  • Either a) currently abstinent (e.g., referred from an inpatient 'detox' setting) or b) with the ability, in the clinician's judgment, to achieve and maintain abstinence
  • If female of child-bearing potential, must be using adequate contraception
  • Able to understand study procedures

Exclusion Criteria:

  • Currently opioid dependent or requiring ongoing treatment with opioids for any indication
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00620750
C18816/6067/DP/US
No
Marc Gourevitch, New York University School of Medicine
New York University School of Medicine
Alkermes
Principal Investigator: Marc N Gourevitch, MD NYU School of Medicine
New York University School of Medicine
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP